![CMS Experiment Targets Incentive to Use the Most Expensive DrugÂ](https://cdn.cancerletter.com/media/2016/03/22035516/42-10-money-cms.png)
![CMS Experiment Targets Incentive to Use the Most Expensive DrugÂ](https://cdn.cancerletter.com/media/2016/03/22035516/42-10-money-cms.png)
Cover Story
By Paul Goldberg and Matthew Bin Han Ong
Is Average Sales Price plus 6 percent the right amount to pay doctors under the Medicare Part B program?
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Drugs & Targets
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
Trending Stories
- Before the Olympics were smoke-free, tobacco brand deals ran rampant
- Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications
- Jonathan Gerber named chief clinical officer of NYU Langone Health’s Perlmutter Cancer Center
- Tweaking the existing systems is not the answer to drug shortages